Abstract

Mogamulizumab (MOG) is a humanized anti-CCR4 monoclonal antibody that is highly cytotoxic for adult T-cell leukemia/lymphoma (ATL) cells. Most non-hematological adverse events are cutaneous adverse reactions in ATL patients. We reviewed the medical records of 24 patients with CCR4-positive aggressive ATL who had received MOG treatment. The incidence of MOG-induced cutaneous adverse reactions (MCARs) was 25% (6 patients). Four patients with MCAR had an interesting clinical course, compared with MCARs reported in previous reports. The factors causing MCAR were suspected to be cefepime, cefozopran, and piperacillin/tazobactam. We consider that hypersensitivity reaction to β-lactam antibiotics is involved in a significant proportion of MCARs.


Author Details

Authors

• Takeo Yasu¹
• Yoichi Imai²
• Nobuhiro Ohno²
• Kaoru Uchimaru³
• Yosuke Kurokawa¹
• Arinobu Tojo²

Departments

• ¹ Department of Pharmacy,
• ² Department of Hematology/Oncology, 
The Institute of Medical Science, and
• ³ Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, 
Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan

Address

Takeo Yasu, PhD

Department of ­Pharmacy
The Institute of Medical Science
The University of Tokyo
4-6-1, Shirokanedai, ­Minato-ku, Tokyo 108-8639, Japan
Email: 
yasutakeo-tky@
umin.ac.jp

Citation